A confirmatory trial on concomitant radiotherapy and transcatheter arterial embolization to reduce skeletal-related events (SRE) related to bone metastasis from renal cell carcinoma.

Joichi Heianna0 sites52 target enrollmentJanuary 11, 2022

Overview

No summary available.

Registry

who.int

Start Date

January 11, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Joichi Heianna

•1\. Clinically diagnosed bone metastasis of renal cell carcinoma (with or without biopsy tissue diagnosis).
•2\. Bone metastases are located in the thoracic spine, lumbar spine, pelvis, or ribs. The number of bone metastases is not required.
•3\. No spinal cord compression syndrome due to bone metastasis in the vertebral body evident on CT or MRI within one week prior to enrollment (asymptomatic is acceptable).
•4\. No history of previous radiotherapy in the treated area.
•5\. Patients must be expected to survive for at least 3 months after radiotherapy followed by TAE (if the prognosis is not promising, there will be no difference in the treatment effect compared to radiotherapy alone).
•6\. The eGFR of at least 30 ml/min and platelets of at least 50,000/dl within 14 days of enrollment.
•7\. Age at the time of obtaining consent must be 20 years or older.
•8\. Written consent has been obtained.

•1\. Allergy to contrast media.
•2\. May be pregnant.
•3\. Has started or will start new chemotherapy or hormonal therapy within 2 weeks of obtaining consent.
•4\. Performance status 4\.
•5\. The principal investigator or sub\-investigator judges that the subject is unsuitable for enrollment in this study.